For the complete documentation index, see llms.txt. This page is also available as Markdown.

WGS Targeted Callers

Generated on 2026-05-07

Targeted Callers

Repetitive regions in the human genome pose a challenge for general variant calling approaches which typically cannot make use of potentially misplaced MAPQ0 reads. Furthermore, high sequence homology of some genes with a pseudogene paralog can lead to a wide variety of common structural variants (SVs) in the population, requiring specialized targeted calling approaches. DRAGEN supports targeted calling for a number of genes/targets as described in subsequent target-specific sections. For more information, refer to the DRAGEN user guide.

DRAGEN: DRAGEN 4.5.4 | Assay: WGS

Performance summary

Targeted caller concordance summary (WGS)

Target
Concordant
Total
Concordance

CYP2D6

211

212

99.5%

SMN1

247

250

98.8%

SMN2

244

250

97.6%

GBA

24

24

100.0%

CYP2B6 (GeT-RM)

70

76

92.1%

CYP2B6 (PacBio HiFi)

123

125

98.4%

CYP21A2

82

84

97.6%

HBA1/2

244

247

98.8%

RHD/RHCE

41

42

97.6%

CYP2D6

Concordant across 211 out of 212 (99.5%) WGS samples with calls from GeT-RM and long read sequencing data.

CYP2D6 concordance by star allele type

Star Allele Type
Number of Samples
Concordance

without SV

90

89 (98.9%)

deletion

15

15 (100%)

duplication

12

12 (100%)

fusion/conversion

26

26 (100%)

Total

143

142 (99.3%)

SMN1/2

Concordant across 247/250 (98.8%) WGS samples for SMN1 and 244/250 (97.6%) WGS samples for SMN2, compared against digital PCR and MLPA.

SMN1 concordance by copy number

SMN1 CN
Total Samples
Concordant

0

42

42 (100%)

1

23

23 (100%)

2

96

94 (97.9%)

3

68

68 (100%)

4

20

20 (100%)

6

1

0 (0%)

Total

250

247 (98.8%)

SMN2 concordance by copy number

SMN2 CN
Total Samples
Concordant

0

26

26 (100%)

1

73

71 (97.3%)

2

92

89 (96.7%)

3

54

54 (100%)

4

5

4 (80%)

Total

250

244 (97.6%)

GBA

Concordant across 24/24 (100%) WGS samples compared against digital PCR and long read sequencing data.

GBA concordance by variant type

Copy Number Change
Recombinant Variant
Total Samples
Concordant

Gain

None

10

10 (100%)

Loss

None

2

2 (100%)

Loss

RecNciI

1

1 (100%)

Loss

A495P

1

1 (100%)

Neutral

L483P

7

7 (100%)

Neutral

c.1263del

1

1 (100%)

Neutral

c.1263del+RecTL

2

2 (100%)

Total

24

24 (100%)

CYP2B6

Concordance against calls from GeT-RM and long read sequencing data. Concordance is based on metabolizer status when multiple genotypes are reported. Two discordant samples in the PacBio comparison are due to a novel star allele (*U1) resulting in multiple possible genotypes.

CYP2B6 concordance by reference source

Star Allele Genotype Source
Number of Samples
DRAGEN Concordance

GeT-RM

76

70 (92.1%)

PacBio HiFi reads

125

123 (98.4%)

CYP21A2

Concordant across 82/84 (97.6%) WGS samples across three benchmark sets with calls from long-range PCR, MLPA and long read sequencing.

CYP21A2 concordance by benchmark set

Benchmark Set
Total Samples
Concordant

Internal

14

13 (92.9%)

1KGP

66

65 (98.5%)

Coriell

4

4 (100%)

Total

84

82 (97.6%)

HBA1/2

Concordant across 244/247 (98.8%) WGS samples compared against long read sequencing data.

HBA1/2 WGS concordance by genotype

HBA Genotype
Total Samples
Concordant

aa/aa

202

199 (98.5%)

-α3.7/aa

31

31 (100%)

--/aa

4

4 (100%)

-α3.7/-α3.7

4

4 (100%)

αααα3.7/aa

3

3 (100%)

-α4.2/aa

2

2 (100%)

αααα4.2/aa

1

1 (100%)

Total

247

244 (98.8%)

LPA

LPA copy number is assessed via allele-specific KIV-2 repeat quantification. Accuracy was evaluated by trio/duo-based inheritance analysis and comparison against Bionano optical mapping.

LPA benchmark: KIV-2 copy number concordance with Bionano and trio inheritance analysis

Figure: (A) Trio-based phased KIV-2 copy number comparison in 120 offspring vs best-matching parental call. (B) Duo-based comparison in 153 offspring. (C) Total copy number vs Bionano optical mapping (n=145). (D) Allelic copy number vs Bionano optical mapping (n=145). Pearson's r and P-value shown per panel.

RHD/RHCE

Concordant across 41/42 (97.6%) WGS samples compared against long read sequencing data.

RHD/RHCE concordance by gene conversion status

RHCE*CE-D(2)-CE Gene Conversion
Total Samples
Concordant

Not present

24

24 (100%)

Heterozygous

10

9 (90%)

Homozygous

8

8 (100%)

Total

42

41 (97.6%)

Star Allele Caller

The Star Allele Caller identifies the genotypes and metabolism status of the following PGx genes that are included in FDA's PGx recommendations or have CPIC Level A designation: CACNA1S, CFTR, CYP2C19, CYP2C9, CYP3A4, CYP3A5, CYP4F2, IFNL3, RYR1, NUDT15, SLCO1B1, TPMT, UGT1A1, VKORC1, DPYD, G6PD, MT-RNR1, BCHE, ABCG2, NAT2, F5 and UGT2B17. For more information, refer to the DRAGEN user guide.

Sample source
# samples
Compare against
Genes tested
Concordance*

1K genomes project

3201

PharmCAT (from DRAGEN gVCF)

DPYD, CACNA1S, UGT1A1, TPMT, CYP3A5, CFTR, CYP2C19, CYP2C9, SLCO1B1, NUDT15, VKORC1, CYP4F2, RYR1, IFNL3

100%

Coriell

96

PharmCAT (from DRAGEN gVCF)

DPYD, CACNA1S, UGT1A1, TPMT, CYP3A5, CFTR, CYP2C19, CYP2C9, SLCO1B1, NUDT15, VKORC1, CYP4F2, RYR1, IFNL3

100%

Coriell

96

GeT-RM (using orthogonal methods)

CYP2C19, CYP2C9, CYP3A5, CYP4F2, TPMT

94%*

1K genomes project

100

Aldy (from BWA/GATK BAM)

G6PD, CFTR, IFNL3, TPMT, VKORC1

100%

* Truth set from 2016; 6% calls from outdated star allele definition.

Last updated

Was this helpful?